Benchmark Upgrades AbCellera Biologics to Buy
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy, indicating a positive outlook on the company's stock.
February 22, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbCellera Biologics upgraded by Benchmark from Hold to Buy, suggesting a bullish outlook on the stock.
The upgrade from Hold to Buy by a Benchmark analyst directly impacts investor sentiment towards AbCellera Biologics, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100